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Abstract
Background: It is well known that a persistent infection with high-risk human papillomavirus
(hrHPV) is causally involved in the development of squamous cell carcinomas of the uterine cervix
(CxSCCs) and a subset of SCCs of the head and neck (HNSCCs). The latter differ from hrHPV-
negative HNSCCs at the clinical and molecular level.
Methods: To determine whether hrHPV-associated SCCs arising from different organs have
specific chromosomal alterations in common, we compared genome-wide chromosomal profiles
of 10 CxSCCs (all hrHPV-positive) with 12 hrHPV-positive HNSCCs and 30 hrHPV-negative
HNSCCs. Potential organ-specific alterations and alterations shared by SCCs in general were
investigated as well.
Results: Unsupervised hierarchical clustering resulted in one mainly hrHPV-positive and one
mainly hrHPV-negative cluster. Interestingly, loss at 13q and gain at 20q were frequent in HPV-
positive carcinomas of both origins, but uncommon in hrHPV-negative HNSCCs, indicating that
these alterations are associated with hrHPV-mediated carcinogenesis. Within the group of hrHPV-
positive carcinomas, HNSCCs more frequently showed gains of multiple regions at 8q whereas
CxSCCs more often showed loss at 17p. Finally, gains at 3q24-29 and losses at 11q22.3-25 were
frequent (>50%) in all sample groups.
Conclusion: In this study hrHPV-specific, organ-specific, and pan-SCC chromosomal alterations
were identified. The existence of hrHPV-specific alterations in SCCs of different anatomical origin,
suggests that these alterations are crucial for hrHPV-mediated carcinogenesis.
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Background
In the pathogenesis of uterine cervical cancer the neces-
sary and causal involvement of high-risk types of the
human papillomavirus (hrHPV) is widely accepted and
supported by strong epidemiological and molecular evi-
dence [1]. HrHPV is present in virtually all cervical carci-
nomas and the viral oncogenes E6 and E7 are consistently
expressed in cervical cancers and precancers. Deregulated
expression of these oncogenes in the basal, dividing cells
of the epithelium interferes with cell cycle control due to
their ability to induce degradation of the tumour suppres-
sor proteins p53 and pRb, respectively. This results in
uncontrolled cell proliferation and accumulation of spe-
cific (epi)genetic changes in the host cell genome, driving
progression to a malignant phenotype [2,3]. In a previous
study we have used array-based comparative genomic
hybridisation (array CGH) to determine frequent chro-
mosomal alterations in cervical cancer, which included
gains at 1q, 3q and 20q and losses at 8q, 10q, 11q, and
13q [4]. The necessity of these and other additional
(epi)genetic alterations in the carcinogenic process is
illustrated by the fact that their frequency increases with
increasing severity of cervical disease.
On the other hand, head and neck squamous cell carci-
noma (HNSCC) is known to be mainly caused by well-
established life-style related habits, such as tobacco and
excessive alcohol consumption. However, besides the
influence of these life-style carcinogens, high risk human
papillomavirus (hrHPV) is present in 15–35% of
HNSCCs and has been suggested to be a separate aetiolog-
ical factor in head-and-neck carcinogenesis [5-8]. Several
studies have shown that hrHPV-positive HNSCCs are
associated with a better clinical outcome [7-9]. Moreover,
molecular differences were found between hrHPV-posi-
tive and hrHPV-negative HNSCCs, supporting the idea of
two separate carcinogenic pathways to HNSCC, one deter-
mined by life-style carcinogens and the other by hrHPV
[5,6,10-13].
In a previous study, using array CGH, we identified a
number of chromosomal alterations specific for hrHPV-
negative HNSCCs that were absent in hrHPV-positive
HNSCCs, including loss at 3p, 5q, and 9p, and amplifica-
tions at 11q [13]. The hrHPV-positive HNSCCs were char-
acterised by a lower level of chromosomal alterations,
none of which were hrHPV-specific. To investigate poten-
tial organ-independent, hrHPV-associated chromosomal
alterations, genomic profiles of cervical SCCs (CxSCCs),
hrHPV-positive and hrHPV-negative HNSCCs were com-
pared using sophisticated clustering and statistical
approaches [4,13]. In addition, we also investigated the
presence of organ-specific alterations and alterations
shared by all SCCs included in this study.
Methods
CGH microarrays
We used chromosomal profiles of 30 hrHPV-negative
HNSCCs, 12 hrHPV-positive HNSCCs and 10 CxSCCs all
of which were previously described (Table 1) [4,13,14].
To avoid possible confounding of our results, we excluded
a subset of hrHPV-negative HNSCCs described in Smeets
et al, which showed little to no alterations and should
therefore be considered a separate group [14].
CGH BAC microarrays produced at the Microarray facility
of the VU Medical Center were used. These arrays included
the 1 Mb resolution Sanger BAC clone set and a subset of
clones from the Children's Hospital Oakland Research
Institute (CHORI). Spots were quantified using ImaGene
5.6.1 software (BioDiscovery Ltd, Marina del Rey, CA,
USA) with default settings for the flagging of bad quality
spots.
The entire dataset described here is available from the
Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/projects/geo/) through series
accession numbers GSE6473 (CxSCC) and GSE12020
(HNSCC).
This study followed the ethical guidelines of the Institu-
tional Review Board of the VU University Medical Center
and informed consent was obtained from all patients
included.
Array CGH analysis
Calling of gains and losses
BAC clones were positioned along the genome according
to the May 2004 freeze. After exclusion of clones with one
or more flagged spots, the average of the triplicate spots
was calculated for each BAC clone. Log2 ratios were nor-
malised per spotted sub-array by subtraction of the
median value of all BAC clones spotted within that sub-
array. Segmentation and subsequent calling of gained,
amplified and lost regions was done using CGHCall, an
automated calling algorithm. Segments with a probability
score of ≥ 0.5 were considered gained, amplified or lost
[15].
Reduction of dataset into chromosomal regions
We used the CGHregions algorithm to reduce our dataset
to chromosomal regions, accepting maximally 0.1%
information loss (Threshold = 0.001). It was shown by
Van de Wiel et al that the use of regions instead of single
BAC clones improved the effectiveness of subsequent sta-
tistical analyses and facilitated interpretation of the results
[16].BMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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Clustering analysis
The samples were clustered by means of a modified ver-
sion of WECCA [17]. WECCA is a hierarchical clustering
method tailor-made for called aCGH data. The modified
version accommodates the use of call probabilities
instead of calls. The use of the call probabilities in the
unsupervised analysis will give a more subtle picture of
the similarities and differences between the samples. The
modified version of WECCA defines the distance between
two features as the symmetric Kullback-Leibler diver-
gence. The distance between the call probability profiles
of two samples is then defined as the average of these
divergences over all features. In the construction of the
dendrogram we used Ward's linkage as it yields compact
and well-separated clusters.
Statistical analysis
The association between clustering results and HPV status
was determined by chi-square testing. The average total
number of altered regions was compared between HPV-
positive and HPV-negative carcinomas using the non-par-
ametric Mann Whitney test. Two-sided p-values below
0.05 were considered statistically significant. Alteration
patterns between HPV-positive (HNSCCs and CxSCCs)
and HPV-negative tumours as well as between HNSCCs
and CxSCCs were compared using a binomial differential
proportion test. The test procedure includes a permuta-
tion-based false discovery rate (FDR) correction for multi-
ple testing, needed to discriminate real differences from
chance effects [18]. An FDR below 0.10 was considered
statistically significant.
Gene ontology analysis
To interpret the biological significance of the genes that
are located at altered chromosomal regions of interest, a
gene ontology analysis was performed using Ingenuity
Pathways Analysis (Ingenuity Systems®, Redwood City,
USA). Biological/molecular functions were considered to
be significantly overrepresented if they contained more
than 1 gene and the Benjamini-Hochberg corrected p-
value was p < 0.10 [19].
Results
hrHPV-positive carcinomas cluster together
To obtain an overview of the similarities between sam-
ples, unsupervised hierarchical clustering was performed.
This method enabled us to determine in an unbiased
manner whether chromosomal profiles of hrHPV-positive
HNSCCs were more closely related to hrHPV-negative
HNSCCs or hrHPV-positive CxSCCs.
As is shown in Figure 1, two clusters emerged. Cluster 1
contained 24 samples, 18 of which were hrHPV-positive
Table 1: Summary of clinical data of carcinomas included in this 
study.
Sample ID origin hrHPV (+/-) age (yrs) sex
CxSCC2 cervix + 39 female
CxSCC4 cervix + 62 female
CxSCC12 cervix + 44 female
CxSCC15 cervix + 47 female
CxSCC27 cervix + 49 female
CxSCC28 cervix + 48 female
CxSCC32 cervix + 37 female
CxSCC36 cervix + 72 female
CxSCC38 cervix + 51 female
CxSCC39 cervix + 40 female
HNSCC9741 oropharynx - 53 female
HNSCC9762 oral cavity - 76 female
HNSCC9773 oral cavity - 49 male
HNSCC9830 oral cavity - 42 male
HNSCC9848 oropharynx - 59 male
HNSCC9892 oral cavity - 67 male
HNSCC9897 oral cavity - 72 male
HNSCC9902 oral cavity - 53 female
HNSCC9942 oral cavity - 55 female
HNSCC9952 oral cavity - 61 female
HNSCC9956 oral cavity - 38 male
HNSCC2014 oral cavity - 68 female
HNSCC2034 oral cavity - 45 female
HNSCC9738 oral cavity - 60 male
HNSCC9745 oropharynx - 52 male
HNSCC9750 oral cavity - 65 male
HNSCC9812 oral cavity - 65 female
HNSCC9827 oropharynx - 57 male
HNSCC9829 oral cavity - 74 female
HNSCC9831 oral cavity - 55 male
HNSCC9841 oropharynx - 55 female
HNSCC9847 oropharynx - 57 male
HNSCC9880 oral cavity - 71 female
HNSCC9907 oral cavity - 46 male
HNSCC9914 oropharynx - 78 male
HNSCC9926 oropharynx - 60 male
HNSCC9957 oral cavity - 51 male
HNSCC9970 oral cavity - 49 female
HNSCC9981 oropharynx - 55 female
HNSCC9987 oral cavity - 79 male
HNSCC9881 oral cavity + 51 male
HNSCC9729 oropharynx + 52 male
HNSCC9838 oropharynx + 60 male
HNSCC9860 oropharynx + 67 female
HNSCC9901 oropharynx + 57 female
HNSCC9948 oropharynx + 70 male
HNSCC9951 oropharynx + 46 male
HNSCC9808 oral cavity + 46 male
HNSCC9859 oral cavity + 40 male
HNSCC9924 oral cavity + 41 female
HNSCC9947 oral cavity + 72 male
HNSCC2015 oral cavity + 65 maleBMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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Result from the unsupervised hierarchical clustering analysis Figure 1
Result from the unsupervised hierarchical clustering analysis. Cluster 1 contains in majority hrHPV-positive carcino-
mas, as is indicated by the black boxes in the legend underneath the heatmap (p < 0.0001).BMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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(75%) and 6 were hrHPV-negative. Cluster 2 contained 28
samples of which 4 samples were hrHPV-positive and 24
were hrHPV-negative (86%). This association between
cluster assignment and hrHPV status was statistically sig-
nificant (p < 0.0001). The hrHPV-positive cluster 1
included both samples of cervical (n = 8) and head and
neck origin (n = 10), indicating similarities between the
chromosomal profiles of hrHPV-induced carcinomas of
different anatomical origins. Within cluster 1, however, 7
out of 8 cervical samples formed a separate sub-cluster.
This suggests that organ-specific alterations exist as well in
hrHPV-positive HNSCCs and CxSCCs.
hrHPV-associated loss at chromosome 13q and gain at 20q
To assess the differences between all three sample groups,
the frequency of gains (including amplifications) and
losses was analysed for all chromosomal regions (Figure
2). In general, hrHPV-negative carcinomas showed signif-
icantly more altered regions than hrHPV-positive carcino-
mas (p = 0.022).
To determine hrHPV-specific chromosomal alterations,
the frequency of alterations was compared between
hrHPV-positive (12 HNSCCs and 10 CxSCCs) and
hrHPV-negative tumours (30 HNSCCs) for all chromo-
somal regions. Regions showing a significant difference
(FDR < 0.10) in this comparison are shown in Table 2.
Interestingly, loss of 13q21.1-21.33 and gain of 20p12.1-
q13.33 were significantly more frequent in HPV-positive
SCCs compared to hrHPV-negative HNSCCs (66.7% and
58.5% in hrHPV-positive SCCs compared to 33% and
24% in hrHPV-negative SCCs, respectively). As was also
shown in our previous study, loss of regions at 3p and 5q,
and gains/amplifications of a small region at 11q
(CCND1 locus) were specific for hrHPV-negative
HNSCCs [13]. A region at 8p showed loss in hrHPV-neg-
ative HNSCCs, gain in hrHPV-positive HNSCCs and no
alteration in CxSCCs. Gain at chromosome 8q was more
frequent in hrHPV-negative HNSCCs, which was due to
absence of this alteration in CxSCCs.
Our unsupervised classification results indicated that,
within our hrHPV-positive cluster, CxSCCs formed a sep-
arate group. To identify potential organ-specific altera-
tions, we therefore also compared the frequency of
alterations for all regions between hrHPV-positive
HNSCCs (n = 12) and CxSCCs (n = 10) (Table 3). Gains
at 3q and losses at 17p were significantly more frequent in
CxSCCs than HNSCCs (FDR < 0.10). On the other hand,
HNSCCs showed frequent gains at chromosome 8q and
losses at 11q. It is important to note that even though gain
at 3q and loss at 11q were significantly different between
hrHPV-positive HNSCCs and CxSCCs, these alterations
were frequent in all sample groups (>50%). Significant
differences for these regions can mainly be explained by
the fact that the size of the exact altered region differed
between groups. Therefore, the smallest regions of overlap
between all samples, namely 3q24-29 and 11q22.3-25,
may represent general alterations in carcinomas derived
from squamous epithelium.
All results described above are summarised in a Venn dia-
gram, showing a general overview of the frequently
altered chromosomal arms specific to or common
between the (sub) groups (Figure 3).
Biological functions of genes located within hrHPV-specific 
chromosomal alterations
As described above gain at 20p12.1-q13.33 and loss at
13q21.1-21.33 were significantly more frequent in
hrHPV-positive SCCs compared to hrHPV-negative ones.
In fact, a 4.5 megabase (Mb) region on chromosome 20
(20q11.21-q11.23), and a 2 Mb region on chromosome
13 (13q21.1) formed the smallest regions of overlap
(SRO) at these respective loci when all hrHPV-positive
carcinomas were considered (Figure 4A and 4B). The SRO
at chromosome 20q contains 78 genes and the one at
chromosome 13q contains 6 genes [see Additional file 1].
Within the SRO at chromosome 20, two genes reside, i.e.
NCOA6 and RBM39, which showed elevated expression
in hrHPV16 E7 expressing cells in vitro [20]. Other cancer-
related genes located within this SRO include PIGU, E2F1,
and DNMT3B. The SRO on chromosome 13 encompasses
the PCDH17 gene and a cluster of five identical loci all of
which are predicted to encode proline-rich proteins that
contain several dopamine D4 receptor signatures.
Subsequent gene ontology analysis of all genes located in
these SROs identified a number of significantly overrepre-
sented GO biological/molecular functions, including cell
cycle, cell-to-cell signalling and interaction, cellular
growth and proliferation, and a number of cellular main-
tenance functions (i.e. DNA replication, recombination
and repair, gene expression, cellular function and mainte-
nance, cellular assembly and organisation, cellular com-
promise, cell death, cell morphology, cellular
development, nucleic acid metabolism, and lipid metab-
olism).
Discussion
In the present study we compared genome-wide chromo-
somal profiles of hrHPV-negative HNSCCs, hrHPV-posi-
tive HNSCCs and hrHPV-positive CxSCCs, to determine
whether hrHPV-associated carcinomas of different origins
have similar chromosomal signatures. In addition, poten-
tial organ-specific alterations were determined within the
total group of hrHPV-positive SCCs.
Unsupervised hierarchical clustering resulted in a separate
hrHPV-positive cluster, indicating similarities in the chro-BMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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Frequency plots for all 3 sample groups Figure 2
Frequency plots for all 3 sample groups. The frequency of gains (positive axis) and losses (negative axis) are shown for A. 
hrHPV-negative HNSCCs, B. hrHPV-positive HNSCCs and C. CxSCCs for chromosome 1–22.BMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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mosomal profiles of hrHPV-induced carcinomas. Subse-
quent supervised statistical analysis identified a number
of hrHPV-associated chromosomal alterations, including
gains at 20p13-q13.33 and losses at 13q21.1-21.33,
which were frequent (>50%) in hrHPV-positive carcino-
mas, but were only rarely observed in hrHPV-negative car-
cinomas. In contrast, lost regions at 3p and 5q as well as
amplifications at 11q13.3 (CCND1 locus) were frequent
in hrHPV-negative carcinomas, but not in hrHPV-positive
carcinomas. In our previous study comparing only
hrHPV-positive and hrHPV-negative HNSCCs, the same
regions were identified as well as being specific for hrHPV-
negative HNSCCs [13].
In the present study we found that gains at 20q and losses
at 13q are specific for hrHPV-positive carcinomas of dif-
Table 2: Significantly different chromosomal alterations between hrHPV+ and hrHPV- carcinomas.
HPV+ (HNSCC; CxSCC) HPV-
chromosome Start (Mb) End (Mb) Cytoband FDR % loss % gain % amp % loss %gain %amp
1 1.08 58.69 1p36.33-p32.2 0.08 0.0 26.7 
(15.6; 40.0)
0.0 14.6 5.8 0.0
1 109.78 117.23 1p13.3-p13.1 0.04 0.0 13.6 
(16.7; 10.0)
0.0 17.8 0.0 0.0
2 96.17 97.68 2q11.2 0.08 4.5 (0.0; 10.1) 0.0 0.0 0.0 20.0 0.0
2 165.89 180.53 2q24.3-q31.3 0.06 9.1 (8.3; 10.0) 0.0 0.0 0.0 18.9 0.0
3 0.28 86.18 3p26.3-p12.1 0.00 17.8 
(20.5; 14.6)
9.4 (3.8; 16.2) 0.0 86.2 0.5 0.0
5 51.16 180.57 5q11.2-q35.3 0.00 8.6 (7.5; 10.0) 9.1 (8.3; 10.0) 0.0 61.0 0.3 0.0
7 9.95 25.67 7p21.3-p15.2 0.05 13.6 
(16.7; 10.0)
0.0 0.0 3.3 21.7 0.0
7 65.52 116.45 7q11.21-q31.2 0.03 4.5 (0.0; 10.0) 0.3 (0.6; 0.0) 0.0 4.1 32.1 2.8
8 0.38 34.51 8p23.3-p12 0.02 6.8 (12.5; 0.0) 17.3 (31.7; 0.0) 0.0 48.7 12.0 0.0
8 75.65 93.93 8q21.11-q22.1 0.06 0.0 22.7 (41.7; 0.0) 0.0 3.3 57.8 0.0
8 114.72 145.68 8q23.3-q24.3 0.05 0.3 (0.0; 0.7) 34.4 (55.4; 9.3) 0.0 0.5 70.2 2.1
11 69.18 70.31 11q13.3-q13.4 0.04 11.4 
(12.5; 10.0)
13.6 (0.0; 30.0) 4.5 (8.3; 0.0) 10.0 15.0 41.7




0.0 0.0 33.0 7.0 2.2
14 47.08 61.97 14q21.3-q23.2 0.08 11.4 
(12.5; 10.0)
2.3 (0.0; 5.0) 0.0 8.3 28.3 0.0
14 79.43 86.91 14q31.1-q31.3 0.09 18.2 
(25.0; 10.0)
9.1 (0.0; 20.0) 0.0 6.7 33.3 0.0
18 28.34 75.62 18q12.1-q23 0.03 10.0 (8.3; 12.0) 18.2 
(25.0; 10.0)
0.0 42.7 2.0 0.0
20 15.56 60.28 20p12.1-
q13.33
0.06 1.5 (2.8; 0.0) 58.5 
(41.7; 78.7)
0.0 6.2 24.0 0.0
21 14.68 46.85 21q11.2-q22.3 0.00 1.1 (0.0; 2.5) 25.0 
(14.6; 37.5)
0.0 33.3 2.5 0.0
hrHPV-specific alterations are printed in bold. Alterations specific for hrHPV-negative HNSCCs are italicised. Mb; Megabases, FDR; False Discovery 
Rate, amp; amplification
Table 3: Significantly different chromosomal alterations between hrHPV-positive HNSCCs and CxSCCs.
HNSCC+ CxSCC
chromosome start (Mb) end (Mb) Cytoband FDR % loss % gain % amp % loss %gain % amp
3 112.84 199.07 3q13.2-q29 0.09 0.0 40.6 2.1 0.0 95.6 0.0
8 61.67 74.46 8q12.1-q21.11 0.09 2.1 50.0 0.0 0.0 0.0 0.0
8 94.15 99.29 8q22.1-q22.2 0.09 0.0 50.0 0.0 0.0 0.0 0.0
8 142.29 145.68 8q24.3 0.09 0.0 58.3 0.0 10.0 0.0 0.0
11 98.40 105.02 11q22.1-q22.3 0.09 66.7 0.0 0.0 20.0 30.0 0.0
17 0.91 2.40 17p13.3 0.09 0.0 0.0 0.0 50.0 10.0 0.0
17 19.19 19.29 17p11.2 0.09 0.0 0.0 0.0 50.0 10.0 0.0
Alterations specific for HNSCCs are printed in bold, alterations specific for CxSCCs are italicised. Mb;Megabases, FDR; False Discovery Rate, amp; 
amplificationBMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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ferent anatomical origins. Our previous study, including
only hrHPV-positive and hrHPV-negative HNSCCs, did
not identify these alterations as specific for hrHPV-posi-
tive HNSCCs. However, in the present study a larger
number of hrHPV-negative hrHNSCCs and HPV-positive
SCCs was included. Furthermore, a sophisticated, objec-
tive calling method was presently used to determine
gained and lost regions [15]. Interestingly, in a number of
studies describing hrHPV E6 and/or E7 mediated immor-
talisation of keratinocytes of multiple anatomical origins,
gains of chromosome 20q and losses of chromosome 13q
were consistently observed [20-23]. Low-level gains of
chromosome 20q are suggested to be caused by E7 expres-
sion and consequent inactivation of the pRb pathway in
epithelial cells [20,21,24]. Deletion of part of the long
arm of chromosome 13 is frequently found in a number
of hrHPV-associated tumours, including cervical, anal and
head and neck carcinomas [4,13,25]. Sabbir et al showed
that loss of 13q in HNSCCs was associated with the pres-
ence of hrHPV, which is in agreement with our findings
[26].
In a recent study Pyeon et al showed that the gene expres-
sion patterns of hrHPV-positive HNSCCs and CxSCCs dif-
fered yet shared many changes compared to hrHPV-
negative HNSCCs [10]. Our study shows that the same
holds true on a chromosomal level. Interestingly, 28% of
the genes Pyeon et al found to be differentially expressed
between hrHPV-positive and hrHPV-negative carcinomas
is located within the chromosomal regions identified in
this study and showed expression changes concordant
with the chromosomal alterations. Of these genes, 39%
was located at chromosome 1p, 25% at 5q, and 14% at
3p. The other genes were located at 11q, 18q and 21q.
Only one gene, SYCP2, was located within the hrHPV-spe-
cific chromosomal alterations found in this study (20q),
but was not located within our SRO. To the best of our
knowledge none of the genes are known to directly inter-
act with hrHPVE6 and/or E7 [27,28]. Pathway analysis of
all genes overlapping with our findings identified cell
cycle/proliferation as most overrepresented biological
function, which is in concordance with the observations
made by Pyeon et al [10].
Pathway analysis of all genes located within the hrHPV-
associated SROs at chromosome 20q and 13q found in
this study, again underlined the importance of cell cycle
(replication and proliferation) related genes in hrHPV-
mediated carcinogenesis. This may be related to the con-
tinuous E7-regulated E2F1 activation and is accompanied
by changes in overall cellular maintenance systems, such
as nucleic acid metabolism, as was also found in HPV16
E7 expressing epithelial cells in vitro [20]. Two genes,
NCOA6 and RBM39, overlapped between this in vitro
study and our results, warranting further investigation of
their role in hrHPV-mediated transformation. NCOA6
encodes a transcriptional coactivator interacting with
basal transcription factors, histone acetyltransferases, and
methyltransferases. RBM39 encodes an RNA binding pro-
tein and possible splicing factor and may act as a tran-
scriptional coactivator for the AP-1 transcription activator
complex and estrogen receptors. Other cancer-related
genes at 20q include E2F1, which is specifically targeted
by hrHPV-mediated degradation of pRb, PIGU, which
may play a role in cell cycle control and was identified as
an oncogene in bladder cancer [29], and DNMT3B, a de
novo DNA methyl transferase. We previously showed that
DNMT3B is amplified in the cervical cancer cell line SiHa
and found a correlation between increased DNMT3B gene
copy numbers and elevated mRNA expression in 78% of
CxSCCs [4]. The increased DNMT3B levels are most likely
related to the high frequency of tumour suppressor gene
promoter hypermethylation events during hrHPV-medi-
ated carcinogenesis [30-32]. The SRO at chromosome 13q
includes one known gene, PCDH17, a member of the pro-
tocadherin family, which is a subfamily of the cadherin
superfamily. At present no reports are available describing
interactions between hrHPV and protocadherins. How-
Summary of common and specific chromosomal alterations  in the different sample groups Figure 3
Summary of common and specific chromosomal 
alterations in the different sample groups. Chromo-
some arms showing frequent alterations (>50%) in one or 
more sample groups (hrHPV-positive HNSCCs; hrHPV-nega-
tive HNSCCs; CxSCCs) are shown in a Venn diagram. ↑ indi-
cates gain; ↓ indicates lossBMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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Genomic coordinates of A. losses at chromosome 13 and B. gains at chromosome 20 are shown for all hrHPV-positive carci- nomas Figure 4
Genomic coordinates of A. losses at chromosome 13 and B. gains at chromosome 20 are shown for all hrHPV-
positive carcinomas. Chromosomal alterations in CxSCCs are shown by dashed lines and alterations in hrHPV-positive 
HNSCCs by solid lines. In C. the smallest regions of overlap (SROs) between hrHPV-positive carcinomas at chromosome 13 
and 20 are summarised.BMC Medical Genomics 2009, 2:32 http://www.biomedcentral.com/1755-8794/2/32
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ever hrHPV presence has been related to decreased E-cad-
herin and subsequent impaired immune response [33-
35].
Next to the hrHPV-related common events, organ-specific
alterations for CxSCCs and HNSCCs were identified as
well. CxSCCs more frequently showed loss at 17p, while
HNSCCs were characterised by frequent gains at chromo-
some 8q, harbouring the oncogene c-Myc [36].
Gains at 3q and losses at 11q were found frequently in all
SCCs included in this study, suggesting their involvement
in carcinogenesis of squamous epithelial cells in general.
Interestingly, we previously showed that gains of 3q were
highly frequent in CxSCCs but not in adenocarcinomas of
the same organ, further emphasising that this alteration
may be specific for squamous epithelium [4].
Conclusion
Together with results from previous studies, our findings
support a causal role for hrHPV in the development of a
subset of HNSCCs. Consequently, hrHPV-positive and
hrHPV-negative HNSCCs should be regarded as different
disease entities requiring different diagnostic and thera-
peutic approaches. The fact that hrHPV-associated SCCs
of different organs have chromosomal alterations in com-
mon, suggests that these alterations are crucial for hrHPV-
induced carcinogenesis. Diagnostic and/or therapeutic
targets based on these alterations may therefore be rele-
vant to hrHPV-associated SCCs of all anatomical origins.
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